Skip to main content
main-content
Erschienen in: Endocrine 2/2020

12.05.2020 | Original Article

Albumin binding function is a novel biomarker for early liver damage and disease progression in non-alcoholic fatty liver disease

verfasst von: Lejia Sun, Qing Wang, Meixi Liu, Gang Xu, Huanhuan Yin, Dongyue Wang, Feihu Xie, Bao Jin, Yukai Jin, Huayu Yang, Junying Zhou, Yilei Mao

Erschienen in: Endocrine | Ausgabe 2/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Indicators to assess early liver damage and disease progression in nonalcoholic fatty liver disease (NAFLD) remain unsatisfactory. Albumin binding function has been reported to be an early indicator of liver damage in hepatitis and liver cirrhosis. However, its role in NAFLD patients is unknown.

Methods

An age/sex-matched, case-control study was performed. Albumin-binding capacity (ABiC) and albumin metal ion binding ability, assessed by ischemia modified albumin (IMA), were measured. Correlation analysis was performed to assess the association of albumin binding function with liver function enzymes and noninvasive liver fibrosis markers.

Results

A total of 80 NAFLD patients and 41 healthy controls were included. Albumin binding function was significantly lower in NAFLD (ABiC: 196.00%, p < 0.001; IMA transformed (IMAT): 0.461, p < 0.001; and IMAT/albumin: 0.947 × 10−2, p < 0.001) than controls (ABiC: 211.00%; IMAT: 0.575; and IMAT/albumin: 1.206 × 10−2). Albumin binding function was also found to be significantly different among healthy participants and different severity groups of NAFLD (p < 0.001). Besides, albumin binding function showed positive correlation with BMI (ABiC: r = −0.247, p = 0.011; IMAT: r = −0.243, p = 0.013; IMAT/albumin: r = −0.254, p = 0.009) and FIB-4 index (ABiC: r = 0.230, p = 0.029). The ROC curve suggested that albumin binding function combined with BMI and triglyceride may predict the presence of NAFLD (area under ROC (AUROC) = 0.935, p < 0.001).

Conclusion

Our findings suggest albumin binding function is a novel biomarker for early liver damage and disease progression in NAFLD.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
2.
Zurück zum Zitat L.J. Alferink, J.C. Kiefte-de Jong, N.S. Erler, B.J. Veldt, J.D. Schoufour, R.J. de Knegt, M.A. Ikram, H.J. Metselaar, H. Janssen, O.H. Franco, S. Darwish Murad, Association of dietary macronutrient composition and non-alcoholic fatty liver disease in an ageing population: the Rotterdam Study. Gut 68(6), 1088–1098 (2019). https://​doi.​org/​10.​1136/​gutjnl-2017-315940 CrossRefPubMed L.J. Alferink, J.C. Kiefte-de Jong, N.S. Erler, B.J. Veldt, J.D. Schoufour, R.J. de Knegt, M.A. Ikram, H.J. Metselaar, H. Janssen, O.H. Franco, S. Darwish Murad, Association of dietary macronutrient composition and non-alcoholic fatty liver disease in an ageing population: the Rotterdam Study. Gut 68(6), 1088–1098 (2019). https://​doi.​org/​10.​1136/​gutjnl-2017-315940 CrossRefPubMed
14.
18.
Zurück zum Zitat S. Klammt, H.J. Wojak, A. Mitzner, S. Koball, J. Rychly, E.C. Reisinger, S. Mitzner, Albumin-binding capacity (ABiC) is reduced in patients with chronic kidney disease along with an accumulation of protein-bound uraemic toxins. Nephrol. Dial. Transpl. 27(6), 2377–2383 (2012). https://​doi.​org/​10.​1093/​ndt/​gfr616 CrossRef S. Klammt, H.J. Wojak, A. Mitzner, S. Koball, J. Rychly, E.C. Reisinger, S. Mitzner, Albumin-binding capacity (ABiC) is reduced in patients with chronic kidney disease along with an accumulation of protein-bound uraemic toxins. Nephrol. Dial. Transpl. 27(6), 2377–2383 (2012). https://​doi.​org/​10.​1093/​ndt/​gfr616 CrossRef
19.
Zurück zum Zitat M. Domenicali, M. Baldassarre, F.A. Giannone, M. Naldi, M. Mastroroberto, M. Biselli, M. Laggetta, D. Patrono, C. Bertucci, M. Bernardi, P. Caraceni, Posttranscriptional changes of serum albumin: clinical and prognostic significance in hospitalized patients with cirrhosis. Hepatology 60(6), 1851–1860 (2014). https://​doi.​org/​10.​1002/​hep.​27322 CrossRefPubMed M. Domenicali, M. Baldassarre, F.A. Giannone, M. Naldi, M. Mastroroberto, M. Biselli, M. Laggetta, D. Patrono, C. Bertucci, M. Bernardi, P. Caraceni, Posttranscriptional changes of serum albumin: clinical and prognostic significance in hospitalized patients with cirrhosis. Hepatology 60(6), 1851–1860 (2014). https://​doi.​org/​10.​1002/​hep.​27322 CrossRefPubMed
Metadaten
Titel
Albumin binding function is a novel biomarker for early liver damage and disease progression in non-alcoholic fatty liver disease
verfasst von
Lejia Sun
Qing Wang
Meixi Liu
Gang Xu
Huanhuan Yin
Dongyue Wang
Feihu Xie
Bao Jin
Yukai Jin
Huayu Yang
Junying Zhou
Yilei Mao
Publikationsdatum
12.05.2020
Verlag
Springer US
Erschienen in
Endocrine / Ausgabe 2/2020
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-020-02319-z

Weitere Artikel der Ausgabe 2/2020

Endocrine 2/2020 Zur Ausgabe

Neu im Fachgebiet Innere Medizin

Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Innere Medizin und bleiben Sie gut informiert – ganz bequem per eMail.